Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation (DBCOND0080920)

Identifiers

Synonyms

Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD) / Acute Myeloid Leukemia With FLT3/ITD Mutation

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04240002	A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)	Cytarabine Filgrastim Fludarabine Gilteritinib	treatment	1 / 2	recruiting
NCT02927262	A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission	Gilteritinib	treatment	2	completed
NCT05876832	A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)	No drug interventions	treatment	3	not_yet_recruiting
NCT05024552	Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML	Cytarabine Daunorubicin Gilteritinib	treatment	1	recruiting
NCT01253070	Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia	Cytarabine Daunorubicin Sorafenib	treatment	2	completed
NCT03333486	Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer	Cyclophosphamide Fludarabine	treatment	2	active_not_recruiting
NCT04788420	Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML	Sorafenib	Not Available	Not Available	completed
NCT06222580	SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation	Gilteritinib Revumenib	treatment	1	recruiting
NCT05596968	The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT	Sorafenib	Not Available	Not Available	recruiting
NCT04174612	AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance	Cytarabine Daunorubicin Midostaurin	treatment	3	recruiting
NCT01578109	Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia	Sorafenib	treatment	1	completed
NCT03735875	Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia	Quizartinib Venetoclax	treatment	1 / 2	completed
NCT01028716	Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Cyclophosphamide Filgrastim Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	terminated
NCT02634827	Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation	Decitabine Midostaurin	treatment	2	terminated
NCT05596981	The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT	Sorafenib	Not Available	Not Available	recruiting
NCT01760655	Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies	1,4-Butanediol Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus Therapeutic allogeneic lymphocytes	treatment	2	completed